NATAP: HPV Vaccine Reduced Cancer Risk MSM

[Guest guest]

Subject: NATAP: HPV Vaccine Reduced Cancer Risk MSMPrevention

of Recurrent High-Grade Anal Neoplasia With Quadrivalent Human Papillomavirus Vaccination of Men Who Have Sex With Men: A Nonconcurrent

Cohort Study: "Among patients infected with oncogenic HPV, qHPV was associated with decreased risk of recurrent HGAIN at 2 years after study

entry" - pdf attached - (02/07/12)"MSM with a history of treated HGAIN who received qHPV had a decreased risk of recurrent HGAIN compared with those who did not receive the vaccine. The decreased risk appears to endure for at least 2 years. MSM with a history of treated HGAIN and known oncogenic HPV infection who received qHPV were similarly at decreased risk of recurrent disease for at least 2 years. Unlike previous studies that have looked at primary disease in young MSM, this study evaluated secondary disease in older MSM.....Whereas qHPV appears effective in preventing recurrent disease, it was not effective at preventing all recurrence. Of the 88 vaccinated patients, 12 (13.6%) developed recurrent HGAIN.....This is the first study to show that qHPV decreases HGAIN recurrence, and it suggests that further research be done on the ability of the vaccine to prevent secondary HPV-related disease. The reduction in recurrence of HGAIN after prior treatment has public health implications. We and others have previously demonstrated high recurrence rates after treatment with surgery, topical, and pharmacologic therapy [10, 19, 20]. Given the results of this study, qHPV may be an effective posttreatment adjuvant to prevent recurrent HGAIN. Although the vaccine is currently licensed and recommended for primary prevention of HPV infection in young persons ages 9-26 years, if

our results are confirmed by a randomized, placebo-controlled trial, then indications for vaccination and the age of the target population should be expanded."